CytomX Therapeutics (NASDAQ:CTMX) Stock Price Down 4.2% After Earnings Miss

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) traded down 4.2% during mid-day trading on Tuesday following a weaker than expected earnings announcement. The stock traded as low as $6.42 and last traded at $6.4660. 3,381,211 shares traded hands during trading, a decline of 38% from the average session volume of 5,457,485 shares. The stock had previously closed at $6.75.

The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The business had revenue of $0.66 million during the quarter, compared to analysts’ expectations of $7.33 million. CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 20.65%.

More CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 Varseta‑M expansion showed meaningful activity in heavily pretreated metastatic colorectal cancer (32% response rate at 10 mg/kg Q3W; estimated PFS ~7.1 months) with a manageable safety profile and planned FDA discussions to align on potential registrational trial — this is the primary catalyst for the earlier rally. Read More.
• Positive Sentiment: Multiple firms upgraded or raised price targets after the data (examples: Wedbush, HC Wainwright, JPMorgan noted higher PTs and upgraded ratings), which amplified buying interest and momentum. Read More.
• Neutral Sentiment: Company released its Q4 materials, slide deck and hosted an earnings call discussing the clinical progress and next‑steps (including combination studies and timelines) — useful context for longer‑term investors assessing pathway to a registrational study. Read More.
• Negative Sentiment: CytomX filed for an underwritten public offering to raise $250M (common stock and pre‑funded warrants) — a near‑term dilution risk that likely pressured the stock after the initial data‑driven surge. Read More.
• Negative Sentiment: Q4 results missed expectations (EPS and revenue; EPS -$0.22 vs. est. -$0.08; revenue ~$0.66M vs. est. ~$7.33M), which reinforces near‑term funding needs and contributed to selling pressure. Read More.

Wall Street Analyst Weigh In

CTMX has been the topic of several research analyst reports. Guggenheim reissued a “buy” rating and set a $10.00 target price on shares of CytomX Therapeutics in a research report on Monday, March 9th. HC Wainwright raised their price target on shares of CytomX Therapeutics from $10.00 to $17.00 and gave the stock a “buy” rating in a report on Monday. Barclays lifted their price objective on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 4th. Oppenheimer reissued an “outperform” rating and set a $12.00 price objective on shares of CytomX Therapeutics in a report on Monday. Finally, Piper Sandler upped their target price on CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, CytomX Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. purchased a new stake in shares of CytomX Therapeutics in the first quarter valued at about $39,000. Woodline Partners LP acquired a new position in CytomX Therapeutics in the 1st quarter valued at about $1,054,000. Geode Capital Management LLC raised its stake in CytomX Therapeutics by 103.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,745,176 shares of the biotechnology company’s stock valued at $3,963,000 after acquiring an additional 887,218 shares during the last quarter. Franklin Resources Inc. purchased a new stake in CytomX Therapeutics during the 2nd quarter valued at approximately $13,096,000. Finally, XTX Topco Ltd acquired a new stake in CytomX Therapeutics during the 2nd quarter worth approximately $277,000. 67.77% of the stock is owned by hedge funds and other institutional investors.

CytomX Therapeutics Trading Down 19.3%

The company has a market capitalization of $923.39 million, a PE ratio of -136.25 and a beta of 2.44. The firm has a 50 day simple moving average of $5.26 and a two-hundred day simple moving average of $4.09.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.